Navigation Links
New Report Tackles the Changing Landscape for Alzheimer's Diagnostics and Treatments

SCOTTSDALE, Ariz., Jan. 28 /PRNewswire/ -- MedPredict has published "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.

"Given the size of this patient population and the lack of approved therapeutics for long-term disease control, it is not surprising to see the large number of companies racing to bring Alzheimer's drugs to market," notes MedPredict president Jeff Berk. "Our panel of experts attempts to sort through the hype, and identify the approaches with the most promising early data." Dr. Berk conducted in-depth interviews with a panel of leading experts in Alzheimer's disease as the basis for this report.

In this report, the panel reviews major developments this past year and forecasts the changes they expect to see in the Alzheimer's competitive landscape in 2008. Each panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), plasminogen activator inhibitor-1, anti-TNF, GSK3 and more.

In addition to the drugs highlighted as most interesting by the experts, this report offers a "program guide" of new compounds, reflecting the many and varied mechanisms being pursued to approach diagnosis and treatment of this disease.

Companies/Partnerships discussed in this report: General Electric, Bateman/Holtzman, Bayer-Schering/Avid Radiopharmaceuticals, Satoris, Neurochem, Sanofi-Aventis, Eisai/Pfizer, Novartis, J&J, Debio, TorreyPines, Forest/Merz/Lundbeck/Daiichi-Sankyo, Medivation, Merck, GSK, Neuropharma/Zeltia, Abbott, AstraZeneca, Roche/Memory, EnVivo/Bayer-Schering, Baxter, Elan/Wyeth, Lilly, Pfizer, Eisai/BioArctic, Roche/Morphosys, AC Immune/Genentech, Affiris, AC Immune, Boehringer-Ingelheim/Ablynx, Lundbeck/Pharmexa, Myriad, Lilly/Elan, Wyeth , Schering-Plough, Elan, BMS, TorreyPines, Cellzome/J&J, CoMentis, Sunesis/Merck, Astex/AstraZeneca, Amgen, Wyeth/Amgen, TransTec/Pfizer, Accera, Sirtris, Neuropharma, Prana, Epix/GSK, Elan/Transition Therapeutics

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
2. Varian, Inc. Reports First Quarter 2008 Results
3. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7
6. Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results
7. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
8. Pharmasset Reports Fiscal Year End 2007 Financial Results
9. Avitar Reports Fourth Quarter and Fiscal Year 2007 Financial Results
10. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
11. Imagenetix Reports Results of Offer to Extend Warrants
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):